Ideas

Vitamin-based therapy for glucose homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Hydralazine (PMHL) increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 11/February/2018, 11.34 pm
Vitamin-based therapy for glucose homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Hydralazine (PMHL) increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 11/February/2018, 11.34 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel shows that…

read more

Molecular therapy for Diabetic retinopathy: D-3 Hydroxybutyrate  (D3HB) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 11/February/2017, 12.33 pm
Molecular therapy for Diabetic retinopathy: D-3 Hydroxybutyrate  (D3HB) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 11/February/2017, 12.33 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD):  Lansoprazole promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 10/February/2017, 11.59 pm
Molecular therapy for Non-alcoholic fatty liver disease (NAFLD):  Lansoprazole promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 10/February/2017, 11.59 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Molecular therapy for Stroke:  Pantoprazole (brand name: Protinix), a drug used in the treatment of stomach and duodenal ulcers, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 10/February/2018, 11.36 pm
Molecular therapy for Stroke:  Pantoprazole (brand name: Protinix), a drug used in the treatment of stomach and duodenal ulcers, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 10/February/2018, 11.36 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A recent study from Research Center for Neurobiology and Department of Neurobiology, Xuzhou Medical College, 209 Tongshan Road, Xuzhou, Jiangsu 221004, PR China; and School of Public…

read more

Molecular therapy for pulmonary arterial hypertension: Fenofibrate inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 10/February/2018, 11.23 pm
Molecular therapy for pulmonary arterial hypertension: Fenofibrate inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 10/February/2018, 11.23 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General…

read more

Molecular therapy for Anti-ageing and Lifespan extension:  Atorvastatin, a medication used in the treatment of cardiovascular disease,  increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan via down regulation of its target gene, 10/February/2018, 11.15 pm
Molecular therapy for Anti-ageing and Lifespan extension:  Atorvastatin, a medication used in the treatment of cardiovascular disease,  increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan via down regulation of its target gene, 10/February/2018, 11.15 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Institute for Cell Biology, University of Bonn, Ulrich-Haberland Str.  Bonn, Germany; and Institute for Genetics and CECAD Research Center, University of Cologne, Joseph-Stelzmann…

read more
Start Typing